Merrill: Confidence...
Services: Diversified Services
Genetic Technologies Limited (GENE: NASDAQ)
$3.10 -0.16 | -4.94%
05/21/13 - 03:59 PM ET
Company Cash Flow
| Jun 2012 | Jun 2011 | Jun 2010 | Jun 2009 | |
| Cash Flow From Operating Activities | ||||
|---|---|---|---|---|
| Net Income (Loss) | -5.42M | 963.32K | -7.95M | -6.34M |
| Operating Gains/Losses | -5.28M | 305.45K | -181.71K | -136.24K |
| Extraordinary Gains / Losses | 0.00 | 0.00 | 0.00 | 0.00 |
| (Increase) Decrease In Receivables | 182.69K | 85.81K | 913.26K | -187.64K |
| (Increase) Decrease in Inventories | 0.00 | 0.00 | 0.00 | 0.00 |
| (Increase) Decrease In Other Current Assets | -15.17K | 0.00 | 0.00 | 0.00 |
| (Decrease) Increase In Payables | -214.30K | -86.19K | -818.33K | 300.34K |
| (Decrease) Increase In Other Current Liabilities | 0.00 | -33.02K | -29.38K | 35.50K |
| (Increase) Decrease In Other Working Capital | 194.72K | 44.67K | -328.91K | 107.92K |
| Other Non-Cash Items | 2.18M | 558.81K | 1.52M | -1.30M |
| Net Cash From Continuing Operations | -7.86M | 2.39M | -3.66M | -3.97M |
| Net Cash From Discontinued Operations | 0.00 | 0.00 | 0.00 | 0.00 |
| Cash Provided By Investing Activities | ||||
| Net Cash From Total Operating Activities | -7.86M | 2.39M | -3.66M | -3.97M |
| Sale of Property, Plant & Equipment | 32.21K | 154.66K | 4.23K | 273.00K |
| Cash Used for Investing Activities | ||||
| Sale of Short-Term Investments | 0.00 | 0.00 | 0.00 | 0.00 |
| Purchases of Property, Plant & Equipment | -78.15K | -149.28K | -329.05K | -172.14K |
| Acquisitions | 10.00 | 0.00 | -809.48K | -6.80K |
| Purchases of Short-Term Investments | 0.00 | 0.00 | 0.00 | 0.00 |
| Other Cash from Investing Activities | 549.97K | 0.00 | 0.00 | 0.00 |
| Cash Provided by Financing Activities | ||||
| Net Cash From Investing Activities | 504.04K | 5.38K | -883.42K | -285.04K |
| Issuance of Debt | 1.02M | 0.00 | 0.00 | 0.00 |
| Cash Used for Financing Activities | ||||
| Issuance of Capital Stock | 11.16M | 0.00 | 859.77K | 0.00 |
| Repayment of Long-Term Debt | -1.08M | -336.41K | -191.57K | 0.00 |
| Repurchase of Capital Stock | 0.00 | 0.00 | 0.00 | 0.00 |
| Payment of Cash Dividends | 0.00 | 0.00 | 0.00 | 0.00 |
| Other Financing Charges, Net | 0.00 | 0.00 | 0.00 | -155.43K |
| Net Cash From Financing Activities | 11.11M | -336.41K | 668.20K | -155.43K |
| Effect of Exchange Rate Changes | 129.54K | -133.80K | 30.20K | -60.20K |
| Net Change in Cash & Cash Equivalents | 3.89M | 1.92M | -3.84M | -4.47M |
Portfolios with GENE
- Portfolio NameUser Type
- ContributorBreakout Stocks Of The Week...
- ContributorStocks Under-$10 Moving Hig...
- ContributorStocks Under-$10 Moving Hig...
- ContributorStocks Under-$10 Moving Hig...
- ContributorStocks Under-$10 Moving Hig...
- ContributorStocks Under-$10 Moving Hig...
- Contributor14 Penny Stocks Get Delisti...
- UserExperimental Equities
- UserMBW
- Userann's prorfolio
Latest GENE Headlines from TheStreet
- STUDY VALIDATES BREVAGen MORE ACCURATELY IDENTIFIES BREAST CANCER RISK LEADING TO INCREASED BREAST HEALTH COMPLIANCE 04.15.13 | 12:04 pm
- The Centers For Women's Health In Stamford CT Pioneers Breast Cancer Risk Assessment 03.18.13 | 12:03 pm
- 5 Stocks Ready to Break Out 02.22.13 | 12:02 pm
- 4 Stocks Under $10 Making Big Moves 10.19.12 | 02:10 pm
- 4 Biotech Stocks Under $10 Soaring Higher 09.25.12 | 02:09 pm
- 8 Stocks Under $10 Ripping Higher 01.26.12 | 02:01 pm
- Optimer Soars on Antibiotic Data 11.11.08 | 12:11 pm
- Biotech Buzz: Big Strides in Alzheimer's Drugs
01.10.08 | 05:01 pm - Funny Money 12.10.07 | 01:12 pm
- Ties May Bind Apple's CEO to Board 09.06.06 | 04:09 pm
Press Releases for GENE
- BREVAGen Reclassified 64% Of Intermediate Gail Risk Subjects(1) (Graphic: Business Wire) - Business Wire 04.10.12 | 09:04 am
- Break-Through Invention For Treating Cancer - Business Wire 11.07.11 | 10:11 am
- Genetic Technologies Limited Announces Quarterly Activities Report For The Quarter Ended 30 September 2011 - Business Wire 10.26.11 | 11:10 am
- Genetic Technologies’ BREVAGen™ Changing The Way US Physicians Assess Breast Cancer Risk - Business Wire 10.18.11 | 09:10 am
- Genetic Technologies Limited Appoints Dr. Mervyn Cass As Company Director - Business Wire 10.03.11 | 10:10 am
Partner Headlines for GENE
- Morning Market Losers - Benzinga 11.28.12 | 09:11 am
- Genetic Technologies Executes Covenant Not to Sue And Release Agreement with One Lambda - Benzinga 10.18.12 | 01:10 pm
- 3 Best Biotech Stocks For This Week (Part VI) - Seeking Alpha 10.16.12 | 08:10 am
- Morning Market Movers - Benzinga 09.25.12 | 09:09 am
- Genetic Technologies Moving On News This Morning - Seeking Alpha 08.08.12 | 09:08 am
- Healthcare Business Recap: Merck's Potential AIDS CURE, Genetic Tech SPIKES - Wall St. Cheat Sheet 07.27.12 | 08:07 am
- Genetic Technologies Executes Exclusive Distribution Agreement with Rosetta Genomics - Benzinga 06.01.12 | 01:06 pm
- Netflix, Take-Two Among Stocks Attracting Investors and Traders Now - Wall St. Cheat Sheet 05.23.12 | 02:05 am
- Afternoon Market Top Percentage Gainers and Losers (CAAS, GENE, HNSN, SYMX, TPX, SCOK, QXM, IDIX, AIB, HERO) - Benzinga 04.08.11 | 01:04 pm
